advertisement

WGC-2021

11.16 Vehicles, delivery systems, pharmacokinetics, formulation (59)

Showing records 1 to 25

Display all abstracts in classification 11.16 Vehicles, delivery systems, pharmacokinetics, formulation

Search within classification 11.16 Vehicles, delivery systems, pharmacokinetics, formulation
78156 Reduction in Ocular Hypotensive Eyedrops by Ab Interno Trabeculotomy Improves Not Only Ocular Surface Condition But Also Quality of Vision
Kashiwagi K
Journal of Ophthalmology 2018; 2018: 8165476
78063 Preservatives in glaucoma medication
Steven DW
British Journal of Ophthalmology 2018; 102: 1497-1503
77935 Controlled-release nanotherapeutics: State of translation
Tan YF
Journal of Controlled Release 2018; 284: 39-48
78105 Treatment merits of Latanoprost/Thymoquinone - Encapsulated liposome for glaucomatus rabbits
Fahmy HM
International Journal of Pharmaceutics 2018; 548: 597-608
78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Misiuk-Hojlo M
European Journal of Ophthalmology 2018; 0: 1120672118785280
78129 Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine
Kim SN
Molecular pharmaceutics 2018; 15: 3143-3152
78256 Old and New Drug Classes Expanding To Include Glaucoma Treatments
Kish T
P and T 2018; 43: 489-502
77935 Controlled-release nanotherapeutics: State of translation
Tan YF
Journal of Controlled Release 2018; 284: 39-48
78135 Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma
Li J
International Journal of Nanomedicine 2018; 13: 3975-3987
78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Davis BM
Scientific reports 2018; 8: 11066
78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Pomorska M
European Journal of Ophthalmology 2018; 0: 1120672118785280
78129 Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine
Ko SA
Molecular pharmaceutics 2018; 15: 3143-3152
78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Pahlitzsch M
Scientific reports 2018; 8: 11066
78063 Preservatives in glaucoma medication
Alaghband P
British Journal of Ophthalmology 2018; 102: 1497-1503
78105 Treatment merits of Latanoprost/Thymoquinone - Encapsulated liposome for glaucomatus rabbits
Saad EAES
International Journal of Pharmaceutics 2018; 548: 597-608
78135 Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma
Tian S
International Journal of Nanomedicine 2018; 13: 3975-3987
78156 Reduction in Ocular Hypotensive Eyedrops by Ab Interno Trabeculotomy Improves Not Only Ocular Surface Condition But Also Quality of Vision
Matsubara M
Journal of Ophthalmology 2018; 2018: 8165476
77935 Controlled-release nanotherapeutics: State of translation
Lao LL
Journal of Controlled Release 2018; 284: 39-48
78135 Montmorillonite/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma
Tao Q
International Journal of Nanomedicine 2018; 13: 3975-3987
77935 Controlled-release nanotherapeutics: State of translation
Xiong GM
Journal of Controlled Release 2018; 284: 39-48
78172 Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease
Guo L
Scientific reports 2018; 8: 11066
78109 The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
Mulak M
European Journal of Ophthalmology 2018; 0: 1120672118785280
78063 Preservatives in glaucoma medication
Lim KS
British Journal of Ophthalmology 2018; 102: 1497-1503
78129 Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine
Park CG
Molecular pharmaceutics 2018; 15: 3143-3152
78105 Treatment merits of Latanoprost/Thymoquinone - Encapsulated liposome for glaucomatus rabbits
Sabra NM
International Journal of Pharmaceutics 2018; 548: 597-608

Issue 19-4

Select Issue


advertisement

Oculus